


Figure S2. Kaplan-Meier Survival Curves Comparing 30-Day Survival Between GT Recipients Treated in 2018–2022 Versus 2022–2023



Kaplan-Meier analysis showing 30-day survival among pediatric patients who received granulocyte transfusions (GT), stratified by treatment period. Patients treated during the early implementation era (2018–2022, $n = 7$) were compared with those treated in the routine practice era (2022–2023, $n = 19$). There was no statistically significant difference in survival between groups (log-rank $p = 0.384$), suggesting that the GT-associated survival benefit was consistent across treatment eras and not solely attributable to temporal improvements in supportive care.